ATGAM一般調査

基本情報

NCT ID

NCT06039020

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

1

治験依頼者名

Pfizer

概要

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan. The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM. The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)